Cochrane · systematic review · CD008422
Vitamin D for the management of multiple sclerosis
Jagannath, VA, Filippini, G, Borges do Nascimento, IJ, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Multiple Sclerosis and Rare Diseases of the CNSAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 3 · 60%Low 2 · 40%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings
Population: [People] with [Multiple Sclerosis]
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Annualised relapse rate (ARR) (number of relapses per patient per year) | no estimate extracted | 5 studies · 417 participants | Very low Downgraded: risk of bias, imprecision |
Expanded Disability Status Scale (EDSS) score | no estimate extracted | 5 studies · 221 participants | Very low Downgraded: risk of bias, imprecision |
MRI gadolinium‐enhancing T1 lesions | no estimate extracted | 2 studies · 256 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events | no estimate extracted | 8 studies · 621 participants | Low Downgraded: risk of bias, imprecision |
Minor adverse events | no estimate extracted | 8 studies · 701 participants | Low Downgraded: risk of bias, imprecision |